Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of botaretigene sparoparvovec gene therapy in RPGR-associated X-linked retinitis pigmentosa
NL-OMON59911Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse events, Laboratory assessments and 2 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NL-OMON59911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59911.